Pierga J-Y, Bonneton C, Magdelénat H, Vincent-Salomon A, Nos C, Pouillart P, Thiery J-P
Medical Oncology Department, Institut Curie, 75248 Paris Cedex 05, France.
Br J Cancer. 2003 Aug 4;89(3):539-45. doi: 10.1038/sj.bjc.6601121.
There is increasing statistical evidence that the presence of tumour cells in bone marrow detected by immunocytochemistry represents an important prognostic indicator in breast cancer, but their individual capacity to become clinical metastases is unknown. The aim of this study was to assess the proliferative capacity of these occult metastatic cells in the bone marrow of patients with various stages of breast cancer. We obtained bone marrow aspirates from 60 patients with breast cancer before treatment with chemotherapy: 17 stage II, 12 stage III and 31 stage IV. After bone marrow culture for 6-34 days (median: 17 days) under specific cell culture conditions, viable epithelial cells were detected by cytokeratin staining in 40 patients (66%). Expansion of tumour cells was poorly correlated with tumour cell detection on primary screening (P=0.06). There was a nonsignificant correlation between the number and the presence of expanded tumour cells and the UICC stage of the patients. On primary screening, tumour cell detection was positive in 56% of patients and was correlated with clinical UICC stage (P=0.01). However, with a median follow-up of 23 months, expansion of tumour cells from bone marrow was associated with decreased patient survival (P=0.04), whereas the survival difference according to detection of CK-positive cells on primary screening was not statistically significant. In conclusion, viable tumour cells can be detected in the bone marrow of breast cancer patients. Their proliferative potential could be predictive of outcome and deserves further investigation.
越来越多的统计学证据表明,通过免疫细胞化学检测到的骨髓中的肿瘤细胞是乳腺癌的一个重要预后指标,但其形成临床转移的个体能力尚不清楚。本研究的目的是评估这些隐匿性转移细胞在不同分期乳腺癌患者骨髓中的增殖能力。我们在60例乳腺癌患者化疗前获取骨髓抽吸物:17例II期、12例III期和31例IV期。在特定细胞培养条件下进行6 - 34天(中位数:17天)的骨髓培养后,40例患者(66%)通过细胞角蛋白染色检测到存活的上皮细胞。肿瘤细胞的扩增与初次筛查时肿瘤细胞的检测相关性较差(P = 0.06)。扩增的肿瘤细胞数量及存在情况与患者的UICC分期之间存在不显著的相关性。在初次筛查时,56%的患者肿瘤细胞检测呈阳性,且与临床UICC分期相关(P = 0.01)。然而,中位随访23个月后,骨髓中肿瘤细胞的扩增与患者生存率降低相关(P = 0.04),而根据初次筛查时CK阳性细胞检测的生存差异无统计学意义。总之,在乳腺癌患者的骨髓中可检测到存活的肿瘤细胞。它们的增殖潜能可能预示预后,值得进一步研究。